Global $6.13 Billion CAR-T Cell Therapy Markets, 2017-2020 & 2021-2026: Focus on Yescarta, Kymriah, Tecartus, Breyanzi, Abecma, Others
28 sept. 2021 04h28 HE
|
Research and Markets
Dublin, Sept. 28, 2021 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Markets, Competition Forecast & Opportunities, 2021-2026" report has been added to ResearchAndMarkets.com's offering. ...
Global $15.1 Bn Immuno-oncology Clinical Trials Market to 2028
30 juil. 2021 07h23 HE
|
Research and Markets
Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The "Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Design...
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021
08 juil. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces an Additional Nature Publication for AUTO1
25 mai 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, May 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a...
Global Immuno-Oncology Assays Market (2021 to 2026) - Growing Significance of Companion Diagnostics Presents Opportunities
14 mai 2021 05h23 HE
|
Research and Markets
Dublin, May 14, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Assays Market by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications...
Autolus Therapeutics announces appointment of Martin Murphy as Non-executive Chairman
19 avr. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, April 19, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Global Immuno-Oncology Market Report 2021-2026: Merck's Keytruda (Pembrolizumab) Leads the Market
29 mars 2021 06h53 HE
|
Research and Markets
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Market Analysis, Trends, Opportunities and Unmet Needs - Thematic Research" report has been added to ResearchAndMarkets.com's...
Autolus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
04 mars 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, March 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
24 févr. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market, 2020 Report - Upcoming Product Launches in Adoptive Cell Therapy Segment Hold Future Growth Potential
17 févr. 2021 08h38 HE
|
Research and Markets
Dublin, Feb. 17, 2021 (GLOBE NEWSWIRE) -- The "I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market" report has been added to ResearchAndMarkets.com's offering. This...